Clinical Trial Update: Osteoporosis Prevention With Low Dose Alendronate [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating low-dose alendronate for osteoporosis prevention in individuals with osteopenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteopenia
• Osteoporosis

Drugs mentioned

• alendronate (alendronate)

Snippet

Sponsor: University Hospital of Mont-Godinne | Conditions: Osteopenia | Phase 3 | Status: COMPLETED